184 related articles for article (PubMed ID: 34335926)
1. Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable Alterations.
Yang J; Wang X; Lu J; Chen H; Zhao X; Gao C; Bai Y; Zhang Q; Fu X; Zhang X
J Cancer; 2021; 12(17):5099-5105. PubMed ID: 34335926
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
4. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
Front Oncol; 2021; 11():751106. PubMed ID: 35273907
[TBL] [Abstract][Full Text] [Related]
5. Genomic features of Chinese small cell lung cancer.
Liu J; Zhao Z; Wei S; Li B; Zhao Z
BMC Med Genomics; 2022 May; 15(1):117. PubMed ID: 35596192
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
Hu J; Wang Y; Zhang Y; Yu Y; Chen H; Liu K; Yao M; Wang K; Gu W; Shou T
Cancer Med; 2019 Aug; 8(9):4338-4347. PubMed ID: 31199602
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
Porta C; Pradelli L; Sicari E; Castellani S; Sivakumar S; Sokol E; Montesion M; Wieland T; Rambichler J; Minari R; Tiseo M
Lung Cancer; 2023 Nov; 185():107359. PubMed ID: 37703610
[TBL] [Abstract][Full Text] [Related]
9. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
[TBL] [Abstract][Full Text] [Related]
10. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
[TBL] [Abstract][Full Text] [Related]
11. Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature.
Wen H; Guo QH; Zhou XL; Wu XH; Li J
Front Oncol; 2021; 11():792003. PubMed ID: 35071000
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.
Devarakonda S; Sankararaman S; Herzog BH; Gold KA; Waqar SN; Ward JP; Raymond VM; Lanman RB; Chaudhuri AA; Owonikoko TK; Li BT; Poirier JT; Rudin CM; Govindan R; Morgensztern D
Clin Cancer Res; 2019 Oct; 25(20):6119-6126. PubMed ID: 31300452
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
15. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
16. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
17. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients.
Yang P; Javle M; Pang F; Zhao W; Abdel-Wahab R; Chen X; Meric-Bernstam F; Chen H; Borad MJ; Liu Y; Zou C; Mu S; Xing Y; Wang K; Peng C; Che X
Hepatobiliary Surg Nutr; 2019 Dec; 8(6):604-614. PubMed ID: 31929987
[TBL] [Abstract][Full Text] [Related]
18. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
Hechtman JF; Zehir A; Yaeger R; Wang L; Middha S; Zheng T; Hyman DM; Solit D; Arcila ME; Borsu L; Shia J; Vakiani E; Saltz L; Ladanyi M
Mol Cancer Res; 2016 Mar; 14(3):296-301. PubMed ID: 26660078
[TBL] [Abstract][Full Text] [Related]
19. DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer.
Dai J; Jiang M; He K; Wang H; Chen P; Guo H; Zhao W; Lu H; He Y; Zhou C
Front Oncol; 2021; 11():708294. PubMed ID: 34604048
[TBL] [Abstract][Full Text] [Related]
20. Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations.
Passaro A; Attili I; Rappa A; Vacirca D; Ranghiero A; Fumagalli C; Guarize J; Spaggiari L; de Marinis F; Barberis M; Guerini-Rocco E
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]